Patrick R. O'Neil, Executive Vice President, Chief Legal Officer, and General Counsel of Ionis Pharmaceuticals (IONS), has been a consistent seller of company stock over the past year, with no open-market purchases recorded. Across 53 total filings, his transactions show a clear disposition bias: total sales reached $17.4 million, while acquisitions—almost entirely option exercises and restricted stock grants—amounted to just $43,175. The most recent 12 transactions were all sales, reinforcing a pattern of steady monetization of equity compensation rather than new investment in the company.
The selling activity has been concentrated in the last several months, with notable clusters around quarterly vesting periods. In late September and early October 2025, O'Neil executed a series of large sales, including $2.33 million on October 2, $2.04 million on the same day, and $958,976 on September 30, each paired with option exercises of similar magnitude—suggesting a sell-to-cover or cash-out strategy following the conversion of options. More recently, he sold $763,662 in March 2026, $516,154 in January 2026, and $245,520 in June 2026, alongside smaller dispositions of $224,488 and $712,849 in October 2025. The largest single sale was $2.33 million, and the smallest was $64,555, indicating a wide range of transaction sizes but a consistent direction.
The absence of any "P" coded purchases—which would signal conviction buying—combined with the frequency and size of "S" coded sales, paints a picture of an executive systematically reducing his position in IONS. While option exercises and tax-withholding events (coded "M" and "F") are mechanical, the repeated open-market sales, including those not tied to vesting dates, suggest active portfolio management. Over the trailing twelve months, O'Neil has sold shares on at least ten separate occasions, with total proceeds exceeding $17 million, and has not acquired a single share through a discretionary purchase.
AI-assisted summary